

1 **Effectiveness of Nirmatrelvir-Ritonavir for the treatment of**
2 **patients with mild to moderate COVID-19 and at high risk of**
3 **hospitalization: Systematic review and meta-analyses of**
4 **observational studies**

5 Kathiaja Miranda Souza¹, Gabriela Carrasco^{*2}, Robin Rojas-Cortés³, Mariana Michel Barbosa⁴,
6 Eduardo Henrique Ferreira Bambirra⁴, José Luis Castro⁵, Juliana Alvares-Teodoro^{4,6}

7

8 1 Independent Consultant, Belo Horizonte, Brazil.

9 2 Red Argentina Pública de Evaluación de Tecnologías Sanitarias (REDARETS), Neuquén,
10 Argentina.

11 3 Pan American Health Organization, Department of Health Systems and Services, Unit of
12 Medicines and Health Technologies, Washington DC, United States of America

13 4 Postgraduate Program in Medicines and Pharmaceutical Services, , Federal University of Minas
14 Gerais, Belo Horizonte, Minas Gerais, Brazil.

15 5 Fundación para la innovación, la formación, la investigación y el desarrollo comunitario
16 (FUNDEC). San Isidro, S/C de Tenerife. España.

17 6 Department of Social Pharmacy, Faculty of Pharmacy, Federal University of Minas Gerais, Belo
18 Horizonte, Minas Gerais, Brazil.

19 * Corresponding author

20 E-mail: gabi_carrasco@hotmail.com

21

22 **Abstract**

23 **Objective**

24 To assess the effectiveness of nirmatrelvir-ritonavir in the treatment of outpatients with mild to
25 moderate COVID-19 who are at higher risk of developing severe illness, through a systematic review
26 with meta-analyses of observational studies.

27 **Methods**

28 A systematic search was performed, in accordance with the Cochrane search methods, to identify
29 observational studies that met the inclusion criteria. The outcomes of mortality and hospitalization
30 were analyzed. Search was conducted on PubMed, EMBASE, and The Cochrane Library. Two
31 reviewers independently screened references, selected the studies, extracted the data, assessed the
32 risk of bias using ROBINS-I tool and evaluated the quality of evidence using the GRADE tool. This
33 study followed the PRISMA reporting guideline.

34 **Results**

35 A total of 16 observational studies and 1,482,923 patients were finally included. The results of the
36 meta-analysis showed that in comparison to standard treatment without antivirals, nirmatrelvir-
37 ritonavir reduced the risk of death by 62% (OR= 0.38; 95% CI: 0.30-0.46; moderate certainty of
38 evidence). In addition, a 53% reduction in the risk of hospital admission was observed (OR = 0.47;
39 95% CI: 0.36–0.60, with very low certainty of evidence). For the composite outcome of
40 hospitalization and/or mortality, there was a 56% risk reduction (OR=0.44; 95% CI: 0.31-0.64,
41 moderate certainty of evidence).

42 **Conclusion**

43 The results suggest that nirmatrelvir-ritonavir could be effective in reducing mortality and
44 hospitalization. The results were valid in vaccinated or unvaccinated high-risk individuals with
45 COVID-19. Data from ongoing and future trials may further advance our understanding of the

46 effectiveness and safety of nirmatrelvir-ritonavir and help improve treatment guidelines for COVID-

47 19.

48

49 **Introduction**

50 Declared a pandemic by the World Health Organization (WHO) in March 2020, COVID-19
51 (coronavirus disease) has posed a significant challenge to healthcare professionals, managers, and
52 health systems, due to its rapid spread, lack of treatment, severity, and unpredictable nature. As of
53 March 7, 2023, there were 759,408,703 confirmed cases of COVID-19, including 6,866,434 deaths
54 (1).

55 WHO data indicates that about 15% of mild/moderate cases progress to severe disease requiring
56 hospitalization and respiratory support, and 5% of patients develop the critical form requiring
57 admission to the Intensive Care Unit (ICU). The high number of cases has resulted in a massive and
58 sudden influx of patients to emergency services, leading to large number of hospitalizations,
59 requiring isolation, oxygen support, intubation, and invasive mechanical ventilation (2).

60 In Latin America, the COVID-19 pandemic has affected countries differently. Among some of these
61 countries, the reported incidence rate ranged from 4.59% in Jamaica to 25.6% in Chile. In contrast,
62 Peru had the highest case fatality rate (5.1%) and Chile the lowest case fatality rate (1.3%) among the
63 countries analyzed (3).

64 In December 2020, the first dose of the COVID-19 vaccine was administered, and since then, 13.01
65 billion doses have been given worldwide, corresponding to 68.5% of the world's population
66 receiving at least one dose of the vaccine. In Latin America, the proportions of vaccinated
67 individuals vary significantly between countries. While in Jamaica 28.2% of people received at least
68 one dose, and 24.8% received the second dose, in Chile, more than 90% of the population received
69 two doses of the COVID-19 vaccine (1).

70 In the context of the appearance of new variants and, in some countries, low vaccination rates, either
71 due to unavailability or lack of adherence, the existence of medicines capable of controlling
72 symptoms and avoiding hospitalizations and deaths is becoming increasingly under focus. In April
73 2022, the WHO published a new update of the "Guideline Therapeutics and COVID-19: living

74 guideline”. In this publication, WHO made a strong recommendation in favor of nirmatrelvir-
75 ritonavir, for patients with mild and moderate COVID-19 at high-risk of hospital admission,
76 qualifying it as the best therapeutic option for those patients, such as unvaccinated, elderly or
77 immunocompromised patients. The guideline development group concluded that nirmatrelvir-
78 ritonavir represents a superior option as it may be more effective in preventing hospitalization than
79 the alternatives compared (standard treatment, molnupiravir and remdesivir), though with important
80 pharmacokinetic interactions, it apparently has fewer concerns than monupiravir regarding adverse
81 effects , and it is easier to administer than intravenous remdesivir and monoclonal antibodies (4). The
82 Ongoing Living Systematic Review published by Pan American Health Organization (PAHO)
83 presented the same direction of the recommendations (5).

84 It is noteworthy that randomized clinical trials investigating the use of nirmatrelvir-ritonavir in non-
85 hospitalized symptomatic COVID-19 patients with a full COVID-19 vaccination schedule and/or
86 who are at risk of progressing to severe disease have not yet been published (5,6).

87 Nirmatrelvir-ritonavir is a high-cost medicine, the target population is quite large, and in several
88 countries the medicine has yet to be approved for emergency use, marketing or reimbursement into
89 the health system due to the uncertainties and challenges related to its efficacy, further information
90 on safety, high risk (e.g., vaccination status), cost, and resource requirements for administration.

91 In order to support the pharmacotherapeutic committees, health technology assessment agencies, and
92 other decision-making bodies for the management of patients diagnosed with COVID-19 and eligible
93 for treatment with nirmatrelvir-ritonavir in countries, a systematic review for the assessment of the
94 effectiveness of nirmatrelvir-ritonavir was conducted.

95

96 **Materials and methods**

97 **Search strategy**

98 Two independent investigators conducted a thorough literature search on PubMed, EMBASE, and
99 The Cochrane Library. Validated filters for observational studies were applied to each database to
100 ensure relevant results. In addition, searches were conducted on Epistemonikos and ClinicalTrials to
101 identify possible systematic reviews and primary studies not retrieved in the main databases. The
102 search strategies developed for each platform are detailed in the Supporting Information (S1 file:
103 Table 1) and were executed until January 4, 2023. The records obtained from the databases were
104 imported into Mendeley® for the identification and elimination of duplicate studies. The report was
105 based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) (S1
106 file: Table 2). This study didn't need the approval of an ethics committee since it is a secondary
107 study (7).

108

109 **Study selection**

110 After exporting a single Mendeley® file, the records were imported into Rayyan (8). Two
111 independent researchers selected the records, and a third evaluator was consulted in case of doubts,
112 both for screening (reading titles and abstracts) and eligibility (reading full texts).

113 The inclusion criteria for this systematic review were: (1) observational studies comparing the use of
114 nirmatrelvir-ritonavir versus standard treatment or no antiviral treatment; (2) involving outpatients
115 with COVID-19 at high risk of developing severe disease as the research population; and (3)
116 determining death and/or hospitalization as the evaluated outcomes. No restrictions were imposed on
117 publication date, language, or follow-up time. Studies reported only in conference proceedings were
118 excluded.

119 The exclusion criteria were: (a) the study was a review article, letters to the editor, comments,
120 consensus documents, clinical trials, pre-clinical studies, animal studies, or case reports; (b) the study
121 did not focus on patients with COVID-19 or the diagnosis was unclear.

122

123 **Data extraction and quality assessment**

124 Two independent researchers performed data extraction using a standardized collection method with
125 Microsoft Office Excel®. A third review author fully checked all extracted data. The following
126 information regarding the demographic characteristics of the studies was collected: first author,
127 publication year, country, study design, general characteristics of the population, time of follow-up,
128 predominant variant of SARS-CoV-2 at the time of the study, diagnostic criteria, number of
129 participants per alternative compared, average age, proportion of male population, proportion of
130 white population, comorbidities, body mass index (BMI), and COVID-19 vaccination status.
131 Additionally, for dichotomous outcomes, data were collected on the number of patients with events
132 in each compared alternative, odds ratio (OR), hazard ratio (HR), relative risk (RR), confidence
133 interval (CI), or p-value.

134 The risk of bias was independently investigated by two researchers using the ROBINS-I tool, which
135 assesses the risk of bias for non-randomized studies (9). Any discrepancies were resolved by
136 consensus. To evaluate publication bias for the primary outcomes, visual inspection of the funnel
137 plot was employed. The quality of evidence was assessed using the GRADE (Grading of
138 Recommendations Assessment, Development and Evaluation) tool (10).

139

140 **Data synthesis and sensitivity analysis**

141 The primary outcomes were hospitalization, mortality and the composite outcome of mortality and/or
142 hospitalization within 35 days. Further subgroup analyses were conducted based on vaccination
143 status and age group. To analyze the data, we used Review Manager® (RevMan) Version 5.4.1
144 (Review Manager, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen,
145 Denmark). The heterogeneity of the results was assessed using the Cochran's Q test and I^2 statistic.
146 If the p-value was less than .05 in the Q statistic and I^2 was $\geq 50\%$, the heterogeneity was
147 considered significant. We used the Mantel-Haenszel statistical method, the Sidik-Jonkman estimator

148 for tau², and the Hartung-Knapp adjustment for the random effects model to calculate pooled odd
149 ratios (ORs) with corresponding 95% confidence intervals (CI). When numerical data were
150 unavailable, we used the PlotDigitizer v3. 2022 free version to extract data from graphs. A sensitivity
151 analysis was conducted to compare the published and unpublished studies, as well as those with and
152 without techniques to adjust for patient characteristics (either through propensity score matching
153 (PSM) or inverse probability treatment weighting (IPTW)).

154 To perform the meta-analyses, we assessed the homogeneity and transitivity by comparing the PICO
155 abbreviations of each study (population inclusion and exclusion criteria, definitions of
156 subpopulations, intervention and controls, and definitions of outcomes). As important discrepancies
157 were identified, we discussed them as possible limitations of the meta-analyses.

158 We presented the characteristics of the studies, the characteristics of the participants, the individual
159 results, and the methodological quality assessment of the included studies in a narrative and
160 descriptive statistical form (absolute and relative frequency, mean and SD or median and
161 interquartile range [IQR]), including tables to assist in the presentation of results. The narrative
162 results were grouped by outcome, highlighting the alternatives compared.

163

164 **Results**

165 **Search results and study selection**

166 From the search strategy used, 182 publications were retrieved, with 162 citations remaining after
167 identifying and eliminating duplicates. All records were subjected to a peer review process, and the
168 full text of 32 potentially eligible articles was carefully considered. Of these 32 studies, 16 original
169 articles were either not observational studies or did not have comparison groups. Therefore, records
170 pertaining to sixteen (16) observational studies were included in the analysis. Fig 1 demonstrates the
171 flow of our studies' selection.

172 **Fig 1. PRISMA Flow chart of literature screening.**

173 **Study characteristics**

174 The sixteen studies finally considered were conducted in 5 countries (Canada, China, United States,
175 Israel, and United Kingdom). Of these, as of the last update of the search, 12 studies were published
176 (11–22) and 4 were unpublished studies (preprint) (23–26). All studies were retrospective cohorts of
177 data obtained from electronic records of hospitals and other healthcare centers, collected from
178 January 2021 to October 2022.

179 For the meta-analysis, fourteen studies were considered. Data from the studies by Wai et al., 2022
180 (n=27,872) and Lewnard et al., 2023 (n=133,426) were not meta-analyzed, as the former did not
181 contain all the necessary data for the proposed meta-analysis and the latter introduced a potential
182 critical bias, as the evaluated cohort was a sample analysis where one or more baseline
183 characteristics were retained in the evaluation, rather than all relevant baseline characteristics for an
184 effectiveness assessment that make the groups minimally comparable. As a result, the cohort was
185 still completely unbalanced (15,26).

186 All patients evaluated in the included studies, eligible for treatment with nirmatrelvir-ritonavir, met
187 the high-risk criteria for progression to severe COVID-19 defined by their respective countries,
188 which included criteria such as age, vaccination status, and presence of comorbidities. In the study
189 by Aggarwal et al., 2023, the decision to seek antiviral treatment was made by patients and
190 physicians, without necessarily meeting the eligibility criteria defined by the United States
191 government (22).

192 Regarding the initiation of treatment with nirmatrelvir-ritonavir, 8 studies were strict with the
193 initiation of treatment within the fifth day of symptom onset or positive COVID-19 test (11,12,17–
194 20,24,25). In the other 6 studies, there was greater flexibility, as patients started treatment with
195 nirmatrelvir-ritonavir within 10 days of symptom onset or positive test (15,16,21–23,26). This was
196 not mentioned in the other two meta-analyzed studies.

197 In total, data from 1,482,923 patients from 14 studies were included in the meta-analysis. The
 198 characteristics of the included studies are shown in Tables 1 and 2.

199 **Table 11: Characteristics of included studies**

Study	Study design	Characteristics of included patients.	Country	Study period	Time of follow-up	Predominant SARS-CoV-variants.	Funding
Ganatra et al., 2022 (11)	retrospective cohort	Adults aged 18 or older who were vaccinated and subsequently contracted COVID-19 at least 1 month after vaccination and were not hospitalized.	United States	1 December 2021 to 18 April 2022	30 days	Not reported	Not reported
Yip et al., 2022 (12)	retrospective cohort	Outpatient patients, regardless of vaccination status, who attended one of the selected clinics	China	16 February 2022 to 31 March 2022	30 days	Omicron	None declared
Wai et al., 2023 (15)	retrospective cohort	Hospitalized and non-hospitalized patients aged 60 years or older or with at least one chronic disease with mild to moderate COVID-19.	China	22 February 2022 to 15 April 2022	30 days	Omicron	The Tung's Foundation, Innovation and Technology Commission of Hong Kong
Hedvat et al., 2022 (16)	retrospective cohort	Non-hospitalized adult solid organ transplant recipients with asymptomatic, mild, or moderate COVID-19.	United States	16 December 2021 to 19 January 2022	30 days	Omicron (BA.1)	Not reported
Dryden-Peterson et al., 2022 (17)	retrospective cohort	Outpatient patients aged 50 years or older with COVID-19.	United States	1 January 2022 to 17 July 2022 to	14 days 28 days	Omicron (BA.1.1, BA.2, BA.2.12.1 y BA.5)	U.S. National Institutes of Health.
Wong et al., 2022 (18)	retrospective cohort	Outpatient patients with mild clinical presentation of COVID-19 and high risk of disease severity.	China	26 February 2022 to 26 June 2022	28 days	Omicron (BA.2.2)	Health and Medical Research Fund
Arbel et al., 2022 (19)	retrospective cohort	Outpatient patients aged 40 years or older with mild clinical presentation of COVID-19 and high risk of disease severity.	Israel	9 January 2022 to 31 March 2022	35 days	Omicron	None declared
Schwartz et al., 2023 (14)	retrospective cohort	Outpatient patients aged 18 years or older with COVID-19.	Canada	4 April 2022 to 31 August 2022.	30 days	Omicron	Ontario Ministry of Health (MOH); the Ministry of Long-Term Care (MLTC); Public Health Ontario
Aggarwal et al., 2023 (22)	retrospective cohort	All non-hospitalized patients within the Colorado healthcare system with a positive test result for SARS-CoV-2.	United States	26 March 2022 to 25 August 2022	28 days	Omicron (BA.2/BA.2.12.1)	U.S. National Institutes of Health
Najjar-Debbiny et al., 2022 (20)	retrospective cohort	Patients ≥18 years old with COVID-19 who are not hospitalized and have at least one comorbidity or condition associated with high risk of severe COVID-19.	Israel	1 January 2022 to 28 February 2022	28 days	Omicron (BA.1)	Not reported
Qian et al., 2022 (13)	retrospective cohort	Patients ≥18 years old with COVID-19 and a diagnosis of systemic autoimmune rheumatic disease.	United States	23 January 2022 to 30 May 2022	30 days	Omicron	Rheumatology Research Foundation
Shah et al., 2022 (21)	retrospective cohort	Patients aged ≥18 years with COVID-19 who are not hospitalized and have at least 1 comorbidity or condition associated with a high risk of severe COVID-19.	United States	1 April 2022 to 31 August 2022	30 days	Omicron	Not reported

Study	Study design	Characteristics of included patients.	Country	Study period	Time of follow-up	Predominant SARS-CoV-variants.	Funding
Bajema et. al., 2022 (23)*	retrospective cohort	Non-hospitalized veteran patients with at least one risk factor, clinical presentation of COVID-19, and high risk of disease severity.	United States	1 January 2022 to 28 February 2022	30 days 31 – 180 days	Omicron (B.1.1.529 y BA1.1)	Veterans Health Administration Health Services Research & Development (HSR&D)
Lewnard et. al., 2023 (26)*	retrospective cohort	Outpatient patients aged 12 years and older with COVID-19 within Kaiser Permanente, Southern California healthcare system.	United States	8 April 2022 to 7 October 2022	30 days 60 days	Omicron (BA.2; BA.4 y BA.5)	US Centers for Disease Control & Prevention National Institute for Allergy and Infectious Diseases of the US National Institutes of Health.
Zhou et. al., 2022 (27)*	retrospective cohort	Outpatient patients aged 12 years and older with COVID-19 within Optum repository, with >700 hospitals and 7000 clinics from all states in the US.	United States	22 december 2021 to 8 May 2022	15 days 30 days	Omicron	Pfizer Inc.
Patel et al., 2022 (24)*	retrospective cohort	Outpatient patients, aged ≥ 12 years at study initiation, and diagnosed with COVID-19	England	1 december 2021 to 31 May 2022	28 days	Omicron (BA.1, BA.2 y BA.5)	GlaxoSmithKline Pharmaceuticals Ltd.

200 * preprint study

201 **Table 22: Characterization of participants included in the studies, according to the evaluated alternative.**

Study	Compared alternatives	Number of participants	Mean age (SD).	Male n (%)	White n (%)	Comorbidities * n (%)	BMC \geq 30 kg/m ² n (%)	Primary series of COVID-19 vaccine and/or boosters n (%)
Ganatra et al., 2022 (11) ^a	Nirmatrelvir-ritonavir for 5 days.	1,130	57.5 (16.3)	418 (37.0)	925 (81.9)	> 50% had at least 1 comorbidity.	237 (21)	1,130 (100)
	Standard treatment	1,130	57.7 (16.3)	406 (35.9)	941 (83.3)	> 50% had at least 1 comorbidity.	208 (18)	1,130 (100)
Yip et al., 2022 (12) ^a	Nirmatrelvir-ritonavir for 5 days.	4,921	70.8 (12.1)	2,247 (45.7)	NR	1,970 (40)	24.0 (4.2) ^{b,d}	42.6 (15.8) ^e
	No antiviral treatment.	4,758	70.5 (12.2)	2,178 (45.8)	NR	1,907 (40)	24.5 (4.7) ^{b,d}	42.8 (15.7) ^e
Wai et al., 2023 (15)	Nirmatrelvir-ritonavir for 5 days.	4,442	4,366 (98,	2,016 (45.4)	NR ^f	> 10% had at least 1 comorbidity.	NR	NR
	No antiviral treatment.	23,430	21,904 (93.5%) ^c	11,078 (47.3)	NR ^f	> 50% had at least 1 comorbidity.	NR	NR
Hedvat et al., 2022 (16)	Nirmatrelvir-ritonavir for 5 days.	28	57.6 (44.3–68.6)	11 (39.3)	NR	28 (100)	25.3 (22.3–30) ^b	23 (82.1)
	No antiviral treatment.	75	53.3 (37.6–64.6)	32 (42.7)	NR	75 (100)	27 (23.3–29.5) ^b	61 (81.3)
Dryden-Peterson et al., 2022 (17) ^a	Nirmatrelvir-ritonavir for 5 days.	11,797	50–64 years – 6,388 (54%) \geq 65 years - 5,408 (46%)	4,880 (41)	10,164 (86)	\leq 3: 6,727 (57) \geq 4: 5,070 (43) ⁱ	4,013 (34)	10,752 (91)
	No antiviral treatment.	32,248	50–64 years - 17,881(55%) \geq 65 years 14,367 (45%)	12,603 (39)	27,266 (85)	\leq 3: 18,464 (57) \geq 4: 13,784 (43) ⁱ	10,661 (33)	29,158 (90)
Wong et al., 2022 (18) ^a	Nirmatrelvir-ritonavir for 5 days.	5,542	4,758 (85.9%) ^c	2,566 (46.3)	NR	0-4: 5291 (95.5) ^k 5-14: 251 (4.5)	NR	1,850 (33.4)
	No antiviral treatment.	54,672	46,601 (85.2%) ^c	25,490 (46.6)	NR	0-4: 52,345 (95.7) 5-14: 1,327 (4.3)	NR	18,138 (33.2)
Arbel et. al, 2022 (19)	Nirmatrelvir-ritonavir for 5 days.	3,902	67.4 (11.2)	1,553 (40)	NR	3,902 (100)	1,626 (42)	3,520 (90)
	No antiviral treatment.	105,352	59.6 (12.8)	41,987 (40)	NR	105,352 (100)	36,140 (34)	81,861 (78)
Schwartz et. al., 2023 (14) ^a	Nirmatrelvir-ritonavir for 5 days.	8,876	74.3 (NI)	3,613 (40.7)	NR	\geq 3 3,805 (42.9) $<$ 3 5,071 (57.1)	NR	8,326 (93.8)
	No antiviral treatment.	168,669	52.4 (NI)	61,733 (36.6)	NR	\geq 3 26,888 (15.9) $<$ 3 141,781 (84.1)	NR	156,525 (92.8)
Aggarwal et al., 2023 (22) ^a	Nirmatrelvir-ritonavir for 5 days.	7,168	18–44 years 3,288 (45.9%) 45–64 years 1,582 (22.1%) \geq 65 years 2,298 (32.1%)	2,966 (41.4)	5,826 (81.3)	4,378 (61.1)	1,924 (26.8)	5,416 (75.5)
	No antiviral treatment.	9,361	18–44 years 5,964 (63.7%) 45–64 years 1,442 (15.4%) \geq 65 years 1,955 (20.9%)	3,899 (41.7)	7,365 (78.7)	4,450 (47.5)	1,793 (19.2)	6,932 (74)
Najjar-Debbiny	Nirmatrelvir-ritonavir for	4,737	68.5 (12.5)	1,992 (42.1)	NR	4,737 (100)	1,938 (40.9)	3,686 (77.8)

Study	Compared alternatives	Number of participants	Mean age (SD).	Male n (%)	White n (%)	Comorbidities * n (%)	BMC \geq 30 kg/m ² n (%)	Primary series of COVID-19 vaccine and/or boosters n (%)
et al., 2022 (20)	5 days.							
	No antiviral treatment.	175,614	53.9 (16.8)	71,967 (41.0)	NR	175,614 (100)	97,938 (55.8)	131,796 (75.0)
Qian et al., 2022 (13)	Nirmatrelvir-ritonavir for 5 days.	307	57.1 (14.9)	72 (23.5)	259 (84.4)	260 (84.4)	27.7 (7.3) ^b	299 (97.4)
	No antiviral treatment.	278	58.3 (15.6)	73 (26.3)	223 (80.2)	234 (84.2)	27.0 (8.3) ^b	260 (93.5)
Shah et al., 2022 (21)	Nirmatrelvir-ritonavir for 5 days.	198,927	18–49 years 56,620 (28.5%) 50–64 years 66,929 (33.6%) \geq 65 years 75,378 (37.9%)	75,984 (38.2)	158,696 (79.8)	182,768 (91.9)	98,892 (49.7)	156,248 (78.5)
	No antiviral treatment.	500,921	18–49 years 221,089 (44.1%) 50–64 years 147,274 (29.4%) \geq 65 years 132,558 (26.5%)	184,184 (36.8)	368,109 (73.5)	463,849 (92.6)	243,331 (48.6)	325,058 (64.9)
Bajema et al., 2022 (23) ^a	Nirmatrelvir-ritonavir for 5 days.	1,587	65.0 (54.0,74.0)	1,412 (89.0)	1,111 (70.0)	1,587 (100)	818 (51.5)	1,050 (66.3)
	No antiviral treatment.	1,587	66.0 (54.0,74.0)	1,416 (89.3)	1,149 (72.4)	1,587 (100)	817 (51.5)	1,035 (65.2)
Lewnard et al., 2023 (26)	Nirmatrelvir-ritonavir for 5 days.	7,274	12–39 años -686 (9.4%) 40–59 años -2,659 (36.6%) \geq 60 años 3,929 (54.0%)	3,080 (42.3)	1,921 (26.4)	3,534 (48.6)	3,253 (44.7)	6,831 (93.9)
	No antiviral treatment.	126,152	12–39 años -44,862 (35.6%) 40–59 años -49,864 (39.5%) \geq 60 años 31,425 (24.9%)	56,357 (44.7)	26,884 (21.3)	6,636 (21.1)	39,482 (31.3)	107,377 (85.1)
Zhou et al., 2022 (27) ^a	Nirmatrelvir-ritonavir for 5 days.	2,808	60.6 (15.8)	1,183 (42.1)	2,381 (84.8)	1.38 (2.2) ^h	1,214 (43.2)	1,897 (67.6) ^g
	No antiviral treatment.	10,849	60.7 (16.7)	4,539 (41.8)	9,132 (84.2)	1.36 (2.3) ^h	4,870 (44.9)	7,207 (66.4) ^g
Patel et al., 2022 (24)	Nirmatrelvir-ritonavir for 5 days.	337	52.6 (15.5)	178 (52.8)	227 (67.4)	337 (100)	5 (1.5) ^j	301 (89.3)
	No antiviral treatment.	4,044	52.4 (17.5)	2,210 (54.7)	1,986 (49.1)	4,044 (100.0)	72 (1.8) ^j	3,488 (86.3)

202 * Cardiovascular diseases; digestive diseases; diabetes mellitus; malignant tumor; nervous system diseases; respiratory diseases; kidney diseases; HIV infection. SD: Standard Deviation; BMI: Body Mass Index; NR:
203 Not Reported. a) Propensity Score Matching (PSM) or Weighted Analytic Cohort matched cohort; b) Mean BMI (SD); c) Studies by Wai et al., 2022, Wong et al., 2022 reported the number of patients over 60 and 65
204 years old (%); d) Yip et al, 2022, refers to BMI data before PSM; e) Rate of complete vaccination specified by age and sex (% and SD); f) 92.6% of the patients are of Chinese ethnicity.; g) Zhou et al., 2022,
205 vaccination status was measured considering at least one dose (\geq 1 dose); h) Deyo-Charlson Comorbidity Index Score; i) Dryden-Peterson et al., 2022 used the Monoclonal Antibody Screening Score - a comorbidity
206 index that predicts the risk of hospitalization from COVID-19; j) Class 3 obesity: BMI \geq 40 kg/m²; k) Charlson Comorbidity Index score

207 **Risk of bias**

208 The included studies were evaluated using the ROBINS-I tool, which assesses the risk of bias in non-
209 randomized studies. The supporting information provides further details on the risk of bias
210 assessments for studies that reported data on mortality, hospitalization, and the composite outcome of
211 hospitalization or mortality. Regarding the mortality outcome, 4 of the 13 included studies had a low
212 risk of bias, while 7 had a moderate risk. However, for the outcome of hospitalization within 35
213 days, 9 of the 11 studies were at risk of serious or critical bias, primarily due to outcome
214 measurement bias (S1 file; Table 3). There was low risk of bias due to missing results or reporting
215 bias.

216

217 **Effectiveness outcomes**

218 Table 3 shows the effect measures reported by the studies included in this review, stratified by
219 subgroup. In the supplementary material (S1 file, Table 4), we report the aggregated results reported
220 and used in the meta-analysis. The following are the results of the meta-analyses conducted by the
221 evaluated outcome.

222

223 **Table 3. Effectiveness results of studies included in the review, by subgroups**

	< 60 years	≥ 60 years	Primary series of COVID-19 vaccine and/or boosters n (%)	Non-vaccinated	Comorbidities	Without comorbidities
Hospitalization						
Aggarwal et al., 2023 ^a	aOR: 0.53 (0.34-0.80)	aOR= 0.37 (0.23-0.57)	aOR=0.47 (0.29-0.74) ^d	aOR= 0.46 (0.27-0.77)	aOR: 0.37 (0.25-0.654)	aOR: 0.68 (0.41-1.12)
Arbel et al., 2022 ^b	aHR: 0.74 (0.35 to 1.58)	aHR: 0.27 (0.15-0.49)	≥ 65 años: aHR: 0.32 (0.17-0.63) < 65 años: aHR: 1.13 (0.50-2.58)	≥ 65 años: aHR: 0.15 (0.04-0.60) < 65 años: aHR: 0.23 (0.03-1.67)	Not reported	NI
Shah et al., 2022	18-49: aHR: 0.59 (0.48-0.71) 50-64: aHR: 0.40 (0.34-0.58)	AHR: 0.53 (0.48-0.58)	≥3 doses: aHR: 0.50 (0.45-0.55) 2 doses aHR: 0.50 (0.42-0.58)	aHR: 0.50 (0.43-0.59)	1 aHR: 0.57 (0.45-0.71) ≥2 aHR: 0.47 (0.44-0.51)	aHR: 0.89 (0.58-1.36)
Qian et al., 2022	aOR: 0.07 (0.02-0.31)	aOR: 0.11 (0.02-0.54)	aOR: 0.09 (0.03 - 0.32)	Not reported	Not reported	Not reported
Yip et al., 2022	Not reported	aHR: 0.76 (0.63-0.92) ^a	Not reported	Not reported	aHR: 0.76 (0.63-0.92) ^c	Not reported
Zhou et al., 2022	aHR: 0.19 (0.09, 0.38)	aHR: 0.17 (0.12, 0.26)	aHR: 0.18 (0.12, 0.28)	NI	Not reported	Not reported
Wong et al., 2022	HR: 0.50 (0.31, 0.81)	HR: 0.80 (0.69, 0.91)	HR: 0.71 (0.51, 1.01)	HR: 0.76 (0.66, 0.87)	Not reported	Not reported
Ganatra et al., 2022	Not reported	Not reported	0.43 (0.2-0.9)	Not reported	Not reported	Not reported
Mortality						
Schwartz et al., 2022 ^d	OR: 0.13 (0.03 - 0.57) ^f	OR: 0.48 (0.39 - 0.59)	1-2 doses: OR 0.23 (0.11 - 0.51) 3+ doses: OR 0.54 (0.43 - 0.67)	OR 0.34 (0.16 - 0.74)	3+: 0.48 (0.34 - 0.67) <3: 0.50 (0.39 - 0.64)	Not reported
Arbel et al., 2022 ^b	aHR: 1.32 (0.16-10.75)	aHR: 0.21 (0.05-0.82)	Not reported	Not reported	Not reported	Not reported
Wong et al., 2022	Not reported	HR: 0.48 (0.32, 0.74)	Not reported	HR: 0.44 (0.30, 0.66)	Not reported	Not reported
Mortality or hospitalization						
Najjar-Debbiny et al., 2022	aHR: 1.06 (0.36-0.73)	aHR: 0.52 (0.36-3.15)	aOR: 0.62 (0.39-0.98)	aOR: 0.52 (0.32-0.82)	Not reported	Not reported
Dryden-Peterson et al, 2022	aRR: 0.55 (0.30 - 1.03)	aRR: 0.55 (0.40 to 0.77)	aRR: 0.69 (0.50 - 0.94)	aRR: 0.19 (0.08 - 0.49)	aRR: 0.56 (0.40 to 0.78) ^e	Not reported
Bajema et al., 2022	aRR: 0.81 (0.46-1.42)	aRR: 0.46 (0.31-0.66)	aRR: 0.48 (0.32-0.73)	aRR:0.61 (0.38-0.97)	Not reported	Not reported
Lewnard et. al., 2022	Not reported	Not reported	HR: 0.45 (0.21 - 0.94)	Not reported	Not reported	Not reported
Schwartz et al., 2023 ^f	OR 0.34 (0.15 - 0.79)	OR 0.55 (0.45 - 0.66)	1-2 doses: OR 0.25 (0.12 - 0.50) 3+ doses: OR 0.62 (0.51 - 0.75)	OR 0.44 (0.23 - 0.84)	3+: 0.54 (0.39 - 0.73) <3: 0.57 (0.46 - 0.71)	Not reported

224 a) Aggarwal et al., 2023 – considered comorbidities 0-1 as with comorbidities; b) Arbel et al., 2022 defined previous immunity to SARS-CoV-2 as
 225 previous vaccination or SARS-CoV-2 infection while the rest of the studies defined it only as previous vaccination; c) Yip et al. al evaluated >60 years
 226 or <60 years with comorbidity; d) Schwartz et al., 2022 analyzed age groups < and > 70 years; e) Dryden-Peterson et al, 2022, Monoclonal Antibody
 227 Screening Score ≥ 4; f) iSchwartz et al., 2022 analyzed age groups of < and > 70 years

228

229 **Mortality**

230 Thirteen studies reported mortality data, including 1,159,467 patients and 7,133 deaths (11,13–
231 19,21–25). In comparison to standard treatment without antivirals, nirmatrelvir-ritonavir reduced the
232 risk of death by 62% (OR= 0.38; 95% CI: 0.30-0.46; moderate certainty of evidence) (Fig 2).

233

234 **Fig 2. Forest plot of all-cause mortality outcome within 35 days - nirmatrelvir-ritonavir versus**
235 **control.**

236

237 Three studies reported subgroup data by vaccination status (11,14,18) and four other studies reported
238 data by age group (14,18,19,24). In the analysis by vaccination status, nirmatrelvir-ritonavir reduced
239 the risk of mortality both in the unvaccinated group (OR=0.41; 95% CI: 0.29-0.58) and in the
240 vaccinated group (OR=0.31; 95% CI: 0.14-0.68), with no significant difference between the groups
241 (Fig 3A).

242 In the subgroup of patients under 60 years of age, there appears to be no difference between
243 treatment with nirmatrelvir-ritonavir compared to standard treatment (OR=0.48; 95% CI: 0.09-2.50),
244 while treating patients over 60 years of age with nirmatrelvir-ritonavir suggests greater protection
245 against the risk of death (OR=0.47; 95% CI: 0.40-0.55) (Fig 3B).

246 It should be noted that the subgroup meta-analysis could only be performed among those studies that
247 reported data that could be grouped. Table 3 presents the results of the effect measures from other
248 studies that reported the evaluation of these subgroups.

249

250 **Fig 3. A: Forest plot of all-cause mortality outcome by vaccination status subgroup. B: Forest**
251 **plot of all-cause mortality outcome by subgroup of age group.**

252

253 Furthermore, the sensitivity analysis did not reveal significant changes in the mortality rate of
254 published studies (OR = 0.42; 95% CI: 0.35–0.50) and unpublished studies (OR = 0.23; 95% CI:
255 0.13–0.42). There were also no significant differences between matched studies (OR = 0.34; 95% CI:
256 0.25–0.47) and unmatched studies (OR = 0.38; 95% CI: 0.27–0.54) (S1 file: Fig 1 and Fig 2).

257

258 **Hospitalization**

259 Eleven studies reported data on hospitalization within 35 days of follow-up after the initiation of the
260 treatment, which included 963,626 patients, with the occurrence of 11,903 events (11–13,17–19,21–
261 25)

262 Compared to standard treatment or no antiviral treatment, the use of nirmatrelvir-ritonavir resulted in
263 a 53% reduction in the risk of hospital admission (OR = 0.47; 95% CI: 0.37–0.60, with very low
264 certainty of evidence) (Fig 4).

265

266 **Fig 4. Forest plot of all-cause hospitalization outcome within 35 days - nirmatrelvir-ritonavir**
267 **versus control.**

268

269 Four studies reported subgroups data by vaccination status (11,18,22,25) and five studies reported
270 age subgroups data (18,19,22,24,25). In the subgroup analysis of state vaccination, nirmatrelvir-
271 ritonavir reduced the risk of hospitalization in both groups, non-vaccinated (OR= 0.41; 95%CI: 0.16-
272 1.05) and vaccinated (OR=0.45; 95%CI: 0.25-0.81). It is worth noting that when using the random
273 effects method, the meta-analysis result introduced greater inaccuracy in the data. Although each
274 study showed a reduction in risk favoring the treatment of nirmatrelvir-ritonavir in the non-
275 vaccinated group, the effect magnitude was very different between the studies in this analysis. In the
276 subgroup analysis by age, nirmatrelvir-ritonavir reduced the risk of hospitalization in both the group
277 of individuals under 60 years (OR=0.45; 95%CI: 0.25–0.82) and the group of individuals over 60

278 years (OR=0.30; CI95%: 0.13–0.70), without a significant difference between the two groups (Fig
279 5).

280

281 **Fig 5. A: Forest plot of all-cause hospitalization outcome within 35 days by vaccination status**
282 **subgroup. B: Forest plot of all-cause hospitalization outcome within 35 days by subgroup of**
283 **age group.**

284

285 The sensitivity analysis revealed significant changes in the hospitalization rate between published
286 studies (OR = 0.57; 95%CI: 0.46–0.71) and unpublished studies (OR = 0.29; 95 %CI: 0.10–0.84).
287 There were also differences between adjusted studies (OR = 0.52; 95 %CI: 0.37–0.73) and not
288 adjusted (OR = 0.29; 95 %CI: 0.15–0.56) (S1 file: Fig 3 and Fig 4).

289

290 **Outcome composed of mortality and/or hospitalization**

291 Five studies reported effectiveness data based on the outcome composed of mortality and/ or
292 hospitalization within 35 days of follow-up after the start of treatment, which included 225,452
293 patients, with the occurrence of 7,019 events (13,14,16,17,23)

294 Compared to standard treatment or no antiviral treatment, nirmatrelvir-ritonavir reduced the risk of
295 mortality or hospitalization by 56% (OR = 0.44; 95% IC: 0.31–0.64, moderate certainty of evidence)
296 (Fig 6).

297

298 **Fig 6. Forest plot of all-cause mortality or hospitalization outcome within 35 days –**
299 **nirmatrelvir-ritonavir versus control**

300 In the subgroup analysis of vaccinated and non-vaccinated individuals, the treatment with
301 nirmatrelvir-ritonavir reduced the risk of mortality or hospitalization by 47% (OR= 0.53; 95%CI:
302 0.39–0.72) and 58% (OR= 0.42; 95%CI: 0.24–0.73), respectively.

303 Among patients under 60 years of age, nirmatrelvir-ritonavir reduced the risk of mortality or
304 hospitalization by 45% (OR= 0.55; 95%CI: 0.36–0.85), while in patients over 60 years of age, it
305 reduced the risk by 46% (OR= 0.54; 95%CI: 0.47–0.61) (Fig 7).

306

307 **Fig 7. A: Forest plot of hospitalization or mortality outcome within 35 days by vaccination**
308 **status subgroup. B: Forest plot of hospitalization or mortality by subgroup of age group.**

309

310 **Certainty of the evidence**

311 The GRADE tool (Grading of Recommendations Assessment, Development and Evaluation) was
312 utilized to assess the quality of evidence. A total of 16 studies were included as evidence, with 14 of
313 these being meta-analyzed for the three primary outcomes of interest. All studies demonstrated
314 significant results in reducing the risk of death and/or hospitalization with the use of nirmatrelvir-
315 ritonavir (Table 4).

316 Regarding the hospitalization outcome within 35 days, the majority of studies exhibited a high risk of
317 bias, thus the overall bias risk domain was considered very serious. The domain of inconsistency was
318 also rated as serious, despite the absence of contrasting results, as the summary of study results
319 revealed considerable heterogeneity ($I^2 = 92\%$, $p < 0.00001$). Conversely, the remaining domains
320 were classified as non-serious due to the absence of studies with discrepant results, and we consider
321 that the summary result was not subject to significant imprecision.

322 In relation to mortality outcomes within 35 days and mortality or hospitalization within 35 days, the
323 majority of studies exhibited a moderate risk of bias and therefore the global risk of bias domain was
324 considered serious. However, the remaining domains were considered non-serious, due to the
325 absence of discrepant results and we considered that the summary result had no important
326 imprecision.

327 Moreover, despite acknowledging that most studies measured mortality and hospitalization outcomes
328 for all causes rather than specifically for COVID-19, it was determined that the domain of indirect
329 evidence would be classified as non-serious for all outcomes. This decision was made due to
330 COVID-19 being a novel disease with poorly elucidated mechanisms, which means that certain
331 hospitalizations and deaths for all causes may be directly linked to COVID-19.

332 Regarding factors that can increase the quality of the evidence, we assessed the publication bias of
333 the main outcome measures by qualitatively evaluating the funnel plot. No significant asymmetries
334 were detected, leading us to conclude that there was no suspicion of publication bias. Since all the
335 included studies used the same dose of nirmatrelvir-ritonavir, it was not possible to detect a dose-
336 response gradient. We considered that there was no residual confounding effect from observational
337 studies that could reduce or increase the demonstrated effect. Moreover, we determined that the
338 magnitude of the effect was not sufficiently large to increase the quality of the evidence.

339 **Table 4. Summary of evidence about treatment with nirmatrelvir-ritonavir versus standard treatment (without antivirals) for COVID-**

Certainty assessment							Nº of patients		Effect		Certainty	Importance
Nº of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Nirmatrelvir-ritonavir	Control	Relative (95% CI)	Absolute (95% CI)		
Hospitalization in 35 days												
11	observational study	very serious ^a	not serious	not serious ^b	not serious	none	1559/234872 (0.7%)	10243/720674 (1.4%)	OR 0.47 (0.36 to 0.61)	7 fewer per 1.000 (from 9 fewer to 5 fewer)	⊕⊕⊕⊕ Very low	IMPORTANT
Mortality in 35 days												
13	observational study	serious ^c	not serious	not serious ^b	not serious	none	218/243297 (0.1%)	6907/908090 (0.8%)	OR 0.38 (0.30 to 0.46)	5 fewer per 1.000 (from 5 fewer)	⊕⊕⊕⊕ Moderate	CRITICAL

											to 4 fewer)		
--	--	--	--	--	--	--	--	--	--	--	-------------	--	--

Mortality or hospitalization in 35 days

5	observational study	serious ^d	not serious	not serious ^b	not serious	none	309/22595 (1.4%)	6710/202857 (3.3%)	OR 0.44 (0.31 to 0.64)	18 fewer per 1,000 (from 23 fewer to 12 fewer)	⊕⊕⊕⊖ Moderate	CRITICAL
---	---------------------	----------------------	-------------	--------------------------	-------------	------	------------------	--------------------	------------------------	--	---------------	----------

341 **CI:** Confidence interval; **OR:** Odds ratio

342 **Explications:**

343 a. Most studies were at serious risk of bias, with the study by Zhou et al., 2022 showing critical risk of bias for the outcome of hospitalization within 30 days using the ROBINS-I tool.

344 b. Do not go down because it is mortality / hospitalization for all causes, since COVID -19 is a new disease in which all the mechanisms that cause possible hospitalizations for other causes are not yet well understood.

345 c. Most of the studies had a moderate risk of bias. However, two studies Aggarwal, et al., 2022 and Patel et al., 2022 showed a high risk of bias for the outcome of 30-day mortality using the ROBINS-I tool. d. All
346 studies showed a moderate risk of bias for the ROBINS-I tool

347

348 **Discussion**

349 The aim of this systematic review and meta-analysis was to evaluate the effectiveness of
350 nirmatrelvir-ritonavir treatment in real-world situations, using observational studies that considered
351 different scenarios of the target population, who were at high risk of hospitalization, such as
352 vaccination status, age group, presence of comorbidities, and other associated risk factors in patients
353 with mild to moderate COVID-19.

354 This study found that nirmatrelvir-ritonavir treatment was linked to a decreased risk of
355 hospitalization and mortality, which is consistent with the results of previous reviews conducted by
356 Amani B et al. and Cheema et al. (28,29). In the same direction as these results, although with a
357 different magnitude, Hammond et al. conducted a phase 2-3 clinical trial (EPIC-HR) to evaluate the
358 efficacy and safety of nirmatrelvir-ritonavir for non-hospitalized adult patients with mild to moderate
359 COVID-19 at high risk of severe illness, resulting in an 88.9% relative risk reduction of
360 hospitalization or death (30). The differences observed in the effectiveness of nirmatrelvir-ritonavir
361 treatment across different populations and contexts reflect the challenges posed by significant
362 interindividual variations in COVID-19. These variations can be influenced by factors such as
363 individual risk, the several mutations in coronavirus genotypes (variants), vaccination coverage,
364 geographic location, and healthcare systems, and can impact hospitalization criteria, timing, and
365 treatment effectiveness. In addition to inherent variations in study methodology, these factors make it
366 challenging to compare studies results across different populations and contexts (31–34). This also
367 means that the issue of discrepancies between results from randomized controlled trials (RCTs) and
368 observational studies can be explained by the obvious efficacy-effectiveness gap and should not
369 promote direct comparisons (35).

370 Aligned with the main findings, subgroup analyses comparing vaccinated and unvaccinated patients
371 indicated a significant reduction in the risk of mortality and hospitalization. Despite the varied
372 vaccination status of the studies included in this review, it was observed that some high-risk patients

373 did not receive a COVID-19 vaccine. In this group, treatment with nirmatrelvir-ritonavir may confer
374 protection against mortality and hospitalization. It is also important to consider that despite the
375 immunological escape of the Omicron variant, the vaccines still provide important protection against
376 COVID-19 (36,37). Moreover, the Omicron variant of COVID-19 has been demonstrated to have
377 lower rates of hospitalization and mortality compared to previous variants. These factors can affect
378 the effect of treatment with Nirmatrelvir-ritonavir (38,39). Additionally, the efficacy of nirmatrelvir-
379 ritonavir use within the context of the availability of bivalent COVID-19 vaccines requires further
380 consideration and evaluation.

381 Our meta-analysis results by age group indicate that nirmatrelvir-ritonavir treatment may provide
382 benefits for both younger and older COVID-19 patients in terms of hospitalization and composite
383 outcome of mortality or hospitalization, suggesting that the findings of this study may be applicable
384 to a broad population. However, in terms of mortality for population under 60 years, the risk
385 reduction could not be confirmed by the meta-analysis. A separate study conducted by Arbel et al.,
386 found that only high-risk COVID-19 positive outpatients aged 65 years and older experienced
387 reduced deaths and hospitalizations with nirmatrelvir-ritonavir treatment. The possible reasons that
388 explain this difference include the study period, taking into account the new variants of COVID-19,
389 hospitalization criteria for young patients, vaccination status, and presence of comorbidities (19,22).

390 This review suggest that nirmatrelvir-ritonavir is effective in treating non vaccinated or vaccinated,
391 non-severe COVID-19 patients with high risk for hospitalization. This may have potential
392 implications for clinicians and decision-makers and could alleviate the pressure on the healthcare
393 system due to COVID-19 hospitalizations. The living clinical guideline developed by the WHO
394 makes a strong recommendation in favor of nirmatrelvir-ritonavir as the first-choice treatment for
395 non-severe patients with a high risk of hospital admission, and the recent update recommends
396 treatment for pregnant and lactating women as well (4). Another COVID-19 antiviral, molnupiravir
397 (Lagevrio®) got a refusal of the marketing authorization by the European Medicines Agency (EMA)

398 on the grounds that the risk-benefit balance could not be established and that it was not possible to
399 identify a specific group of patients in which a clinically relevant benefit could be demonstrated (40).
400 In this scenario, the therapeutic arsenal for treating COVID-19 is more restricted.
401 Treating non-severe patients might be of interest, considering that antiviral drugs may be more useful
402 in non-severe cases of COVID-19, where viral replication is the primary mechanism driving disease
403 progression. This contrasts with severe cases, where the primary cause of illness is an inflammatory
404 response (41–43). Furthermore, a randomized clinical trial conducted by Liu et al. in 2023, which
405 evaluated the efficacy of nirmatrelvir-ritonavir in adult patients hospitalized with SARS-Cov-2
406 (Omicron BA.2.2 variant) infection and severe comorbidities, did not show any additional benefits in
407 terms of all-cause mortality up to day 28 when compared to standard treatment (39).
408 The strengths of our systematic review are several. Firstly, only ambulatory patients considered at
409 high risk of hospitalization were included in the review. Secondly, we conducted subgroup analyses
410 by vaccination status and age group. Thirdly, we updated the data from the included preprint studies
411 that had been published at the time of article writing. Additionally, the study was conducted in
412 accordance with PRISMA guidelines, with the assessment of the risk of bias according to ROBINS-I
413 and the GRADE assessment of available evidence. We conducted our search accounting for the latest
414 publications with broad geographical distribution. To our knowledge, this is the first systematic
415 review with meta-analysis that highlights differences in vaccination status, age group, and
416 comorbidity presence. Our review included studies with heterogeneous populations as compared to
417 the EPIC-HR trial, where 71% of the participants were Caucasians and the high-risk patients were
418 mostly obese. This heterogeneity increases the external validity of our results.
419 Our systematic review also has some limitations. Firstly, all the studies included were retrospective
420 cohorts, which are more susceptible to bias and confounding. However, to mitigate this limitation,
421 most of the studies were matched by propensity score or other balancing methods between groups.
422 Additionally, all the studies underwent assessment by the ROBINS-I bias risk tool, which enabled us

423 to conduct a more rigorous evaluation and determine the confidence of the results using the GRADE
424 method (10). Despite these efforts, the high heterogeneity between the studies and the subgroups
425 evaluated, especially for the outcome of hospitalization within 35 days, suggests the possibility of
426 variations in criteria for patient hospitalization decisions, different COVID-19 variants, patient
427 characteristics, geographical location, and other factors (33,34).

428 A further limitation is that standard treatment or no use of antiviral treatment was considered as the
429 control group in the studies. This may have affected the reported effect size and should be considered
430 when interpreting our results (4).

431 Another limitation of our study is that only a few studies could be meta-analyzed by subgroup, which
432 may distort the actual effect in these specific groups. To address this limitation, we reported effect
433 measures adjusted by studies that conducted such analyses but were not included in the meta-analysis
434 due to the absence of data.

435 The timing of antiviral therapy initiation is a critical consideration for the management of COVID-19
436 patients. The World Health Organization recommends starting treatment within five days of
437 symptom onset (4). However, in the studies we analyzed, the duration of symptoms or the date of
438 positive COVID-19 test before treatment initiation varied widely (up to 10 days), and data on the
439 timing of treatment initiation was often unavailable in some studies. This lack of data poses
440 challenges in interpreting our findings regarding the optimal timing of oral antiviral therapy
441 initiation. Nevertheless, the available evidence suggests that delaying the initiation of nirmatrelvir-
442 ritonavir therapy beyond five days of symptom onset significantly reduces treatment efficacy against
443 hospitalization and death (26,44). It is important to highlight that the beginning of treatment should
444 be accompanied by early diagnosis, and therefore, it is crucial that countries have access to and
445 implement efficient testing programs, especially in low- and middle-income countries (45).

446 Safety data, rebound effect and long-term outcomes of COVID-19 reported in some studies were not
447 included in our analysis. Hammond et al, demonstrated a lower frequency of serious adverse events,

448 and adverse events leading to discontinuation in the Nirmatrelvir-ritonavir group compared to the
449 placebo group. Similarly, the systematic review by Amani et al., demonstrated that there was no
450 significant difference in the incidence of adverse events between the treatment and control groups in
451 their pooled analysis (OR = 2.20; 95% CI: 0.42–11.47) (28,30). In addition, it should be noted that
452 ritonavir is a CYP3A4 inhibitor, an enzyme responsible for metabolizing several medications, and
453 potential drug interactions should be taken into consideration during treatment, especially among
454 poly-treated patients and those who are taking corticosteroids and other immunosuppressive
455 medications (46).

456 Retrospective studies have suggested a low incidence of rebound phenomenon after treatment with
457 nirmatrelvir-ritonavir, which was described in a limited number of individuals, all of whom
458 developed virological rebound approximately between 7 and 30 days after symptom onset and were
459 likely infected with Omicron variants. Among patients who developed symptom rebound after
460 treatment with nirmatrelvir-ritonavir, the clinical presentation was mild and did not require COVID-
461 19 directed therapies (28,47–50). It should be noted that prospective epidemiological studies are still
462 needed to more accurately measure the incidence and risk factors for COVID-19 rebound and
463 compare them in those treated with nirmatrelvir-ritonavir versus those not treated.

464 Finally, considering the potential benefits of treatment with nirmatrelvir-ritonavir and the necessary
465 precautions to guide treatment. There are challenges to consider in the healthcare systems of
466 countries, given that it is an expensive treatment with limited availability. There is a need to further
467 evaluate prioritization, cost-effectiveness and the impact of its use, especially in low and middle-
468 income countries (51,52).

469

470 **Conclusion**

471 The results of our meta-analysis suggest that nirmatrelvir-ritonavir could be effective in reducing
472 hospitalization and/or mortality in high-risk individuals with COVID-19, compared to those who did

473 not receive antiviral treatment, either vaccinated or unvaccinated. Although it is important to mention
474 that the effect on mortality reduction was uncertain for those under 60 years. The present review
475 underscores the critical importance of early initiation of antiviral therapy. It is crucial to
476 acknowledge that there are still several limitations to consider, and additional evidence is necessary
477 to identify the subgroups of patients who may benefit the most from this treatment. It is important to
478 highlight that observational studies are more prone to bias and confounding, and therefore cannot
479 provide conclusive evidence of causality. Data from ongoing and future randomized controlled trials
480 may further expand our understanding of the efficacy and safety of nirmatrelvir-ritonavir and help
481 improve standard treatment guidelines for COVID-19.

482

483 **References**

484

485 1. WHO COVID-19 Dashboard. Geneva: World Health Organization, 2020. Available online:
486 <https://covid19.who.int/> (last cited: [12-02-2022]).

487 2. World Health Organization. (2022). Clinical care for severe acute respiratory infection:
488 toolkit: COVID-19 adaptation, update 2022. World Health Organization.
489 <https://apps.who.int/iris/handle/10665/352851>. Licença: CC BY-NC-SA 3.0 IGO.

490 3. Edouard Mathieu, Hannah Ritchie, Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino,
491 Joe Hasell, Bobbie Macdonald, Saloni Dattani, Diana Beltekian, Esteban Ortiz-Ospina and
492 Max Roser (2020) - “Coronavirus Pandemic (COVID-19)”. [Internet]. [citado 30 de novembro
493 de 2022]. Available at: <https://ourworldindata.org/coronavirus>

494 4. Lamontagne F, Agarwal A, Rochweg B, Siemieniuk RA, Agoritsas T, Askie L, et al. A living
495 WHO guideline on drugs for covid-19. *BMJ*. 4 de setembro de 2020;m3379.

496 5. Pan American Health Organization. Ongoing Living Update of Potential COVID-19
497 Therapeutics Options: Summary of Evidence. Rapid Review. Washington, D.C.: OPS; 2022.
498 Available at: <https://iris.paho.org/handle/10665.2/52719>.

499 6. Consideraciones sobre el uso de antivirales, anticuerpos monoclonales y otras intervenciones
500 para el manejo de pacientes con COVID-19 en América Latina y el Caribe, 26 de abril del
501 2022. Washington, D.C.: OPS; 2022. [Internet]. Available at:
502 https://iris.paho.org/bitstream/handle/10665.2/56002/OPSIMSEIHCOVID-19220016_spa.pdf

503 7. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
504 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 29 de
505 março de 2021;n71.

- 506 8. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for
507 systematic reviews. *Syst Rev*. 5 de dezembro de 2016;5(1):210.
- 508 9. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-
509 I: A tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*.
510 2016;355:4–10.
- 511 10. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: A
512 new series of articles in the *Journal of Clinical Epidemiology*. *J Clin Epidemiol*. abril de
513 2011;64(4):380–2.
- 514 11. Ganatra S, Dani SS, Ahmad J, Kumar A, Shah J, Abraham GM, et al. Oral Nirmatrelvir and
515 Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019 (COVID-
516 19). *Clin Infect Dis*. 20 de agosto de 2022;
- 517 12. Yip TCF, Lui GCY, Lai MSM, Wong VWS, Tse YK, Ma BHM, et al. Impact of the Use of
518 Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019
519 Patients (COVID-19). *Clin Infect Dis*. 29 de agosto de 2022;
- 520 13. Qian G, Wang X, Patel NJ, Kawano Y, Fu X, Cook CE, et al. Outcomes with and without
521 outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune
522 rheumatic diseases: a retrospective cohort study. *Lancet Rheumatol*. março de
523 2023;5(3):e139–50.
- 524 14. Schwartz KL, Wang J, Tadrous M, Langford BJ, Daneman N, Leung V, et al. Population-
525 based evaluation of the effectiveness of nirmatrelvir–ritonavir for reducing hospital
526 admissions and mortality from COVID-19. *Can Med Assoc J*. 13 de fevereiro de
527 2023;195(6):E220–6.
- 528 15. Wai AK-C, Chan CY, Cheung AW-L, Wang K, Chan SC-L, Lee TT-L, et al. Association of

- 529 Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and
530 related avoidable healthcare system cost among high-risk patients with mild to moderate
531 COVID-19. *Lancet Reg Heal - West Pacific*. janeiro de 2023;30:100602.
- 532 16. Hedvat J, Lange NW, Salerno DM, DeFilippis EM, Kovac D, Corbo H, et al. COVID-19
533 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1
534 era. *Am J Transplant*. 18 de novembro de 2022;22(11):2682–8.
- 535 17. Dryden-Peterson S, Kim A, Kim AY, Caniglia EC, Lennes IT, Patel R, et al. Nirmatrelvir Plus
536 Ritonavir for Early COVID-19 in a Large U.S. Health System. *Ann Intern Med*. 13 de
537 dezembro de 2022;
- 538 18. Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness
539 of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-
540 hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-
541 CoV-2 infection during the omicron wave in Hong Kong: a. *Lancet*. outubro de
542 2022;400(10359):1213–22.
- 543 19. Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, et al. Nirmatrelvir Use
544 and Severe Covid-19 Outcomes during the Omicron Surge. *N Engl J Med*. 1 de setembro de
545 2022;387(9):790–8.
- 546 20. Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of
547 Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.
548 *Clin Infect Dis*. 2022;1–8.
- 549 21. Shah MM, Joyce B, Plumb ID, Sahakian S, Feldstein LR, Barkley E, et al. Paxlovid associated
550 with decreased hospitalization rate among adults with COVID-19 - United States, April-
551 September 2022. *Am J Transplant*. janeiro de 2023;23(1):150–5.

- 552 22. Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, et al. Real-world
553 use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants
554 including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. *Lancet Infect Dis.*
555 fevereiro de 2023;
- 556 23. Bajema KL, Berry K, Streja E, Rajeevan N, Li Y, Yan L, et al. Effectiveness of COVID-19
557 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial
558 emulation studies with one-month and six-month outcomes. *medRxiv Prepr Serv Heal Sci.* 16
559 de dezembro de 2022;
- 560 24. Patel V, Yarwood MJ, Levick B, Gibbons DC, Drysdale M, Kerr W, et al. Characteristics and
561 outcomes of patients with COVID-19 at high- risk of disease progression receiving
562 sotrovimab , oral antivirals or no treatment in England. *2022;5:1–38.*
- 563 25. Zhou X, Kelly SP, Liang C, Li L, Shen R, Leister-Tebbe HK, et al. Real-World Effectiveness
564 of Nirmatrelvir/Ritonavir in Preventing Hospitalization Among Patients With COVID-19 at
565 High Risk for Severe Disease in the United States: A Nationwide Population-Based Cohort
566 Study. *medRxiv.* 2022;2022.09.13.22279908.
- 567 26. Lewnard JA, McLaughlin JM, Malden D, Hong V, Puzniak L, Ackerson BK, et al.
568 Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a
569 large US healthcare system. *medRxiv.* 1 de janeiro de 2023;2022.10.02.22280623.
- 570 27. HSS A-S, Koh M-T, Tan KK, Chan LG, Zhou L, Bouckenoghe A, et al. Safety and
571 immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in
572 Malaysia: A randomized, placebo-controlled, Phase III study. *Vaccine.* 2013;31(49):5814–21.
- 573 28. Amani B, Amani B. Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19:
574 A rapid review and meta-analysis. *J Med Virol.* 10 de fevereiro de 2023;95(2).

- 575 29. Cheema HA, Jafar U, Sohail A, Shahid A, Sahra S, Ehsan M, et al. Nirmatrelvir–ritonavir for
576 the treatment of COVID-19 patients: A systematic review and meta-analysis. *J Med Virol.*
577 12 de fevereiro de 2023;95(2).
- 578 30. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral
579 Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *N Engl J Med.*
580 2022;386(15):1397–408.
- 581 31. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al. Estimated
582 Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and
583 Severe Outcomes. *JAMA Netw Open.* 22 de setembro de 2022;5(9):e2232760.
- 584 32. Pereira NL, Ahmad F, Byku M, Cummins NW, Morris AA, Owens A, et al. COVID-19:
585 Understanding Inter-Individual Variability and Implications for Precision Medicine. *Mayo*
586 *Clin Proc.* fevereiro de 2021;96(2):446–63.
- 587 33. Smith KT, Monti D, Mir N, Peters E, Tipirneni R, Politi MC. Access Is Necessary but Not
588 Sufficient: Factors Influencing Delay and Avoidance of Health Care Services. *MDM policy*
589 *Pract.* 2018;3(1):2381468318760298.
- 590 34. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction
591 models for diagnosis and prognosis of covid-19: systematic review and critical appraisal.
592 *BMJ.* 7 de abril de 2020;m1328.
- 593 35. Zhang X, Fu S, Meng R, Ren Y, Shang Y, Tian L. Is there an efficacy-effectiveness gap
594 between randomized controlled trials and real-world studies in colorectal cancer: a systematic
595 review and meta-analysis. *Transl Cancer Res.* novembro de 2020;9(11):6963–87.
- 596 36. Zhang X, Zhang W, Chen S. Shanghai’s life-saving efforts against the current omicron wave
597 of the COVID-19 pandemic. *Lancet.* maio de 2022;399(10340):2011–2.


- 598 37. Rosenberg ES, Holtgrave DR, Dorabawila V, Conroy M, Greene D, Lutterloh E, et al. New
599 COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status - New York,
600 May 3-July 25, 2021. *MMWR Morb Mortal Wkly Rep.* 27 de agosto de 2021;70(34):1150–5.
- 601 38. Madhi SA, Kwatra G, Myers JE, Jassat W, Dhar N, Mukendi CK, et al. Population Immunity
602 and Covid-19 Severity with Omicron Variant in South Africa. *N Engl J Med.* 7 de abril de
603 2022;386(14):1314–26.
- 604 39. Liu J, Pan X, Zhang S, Li M, Ma K, Fan C, et al. Efficacy and safety of Paxlovid in severe
605 adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. *Lancet*
606 *Reg Heal - West Pacific.* fevereiro de 2023;100694.
- 607 40. CHMP. (2023). Refusal of the marketing authorisation for Lagevrio (molnupiravir). European
608 Medicines Agency (2023). [Internet]. Available at:
609 [https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-](https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-lagevrio-molnupiravir_en.pdf)
610 [authorisation-lagevrio-molnupiravir_en.pdf](https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-lagevrio-molnupiravir_en.pdf)
- 611 41. Anka AU, Tahir MI, Abubakar SD, Alsabbagh M, Zian Z, Hamedifar H, et al. Coronavirus
612 disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and
613 management. *Scand J Immunol.* abril de 2021;93(4):e12998.
- 614 42. Pitre T, Jones A, Su J, Helmeczi W, Xu G, Lee C, et al. Inflammatory biomarkers as
615 independent prognosticators of 28-day mortality for COVID-19 patients admitted to general
616 medicine or ICU wards: a retrospective cohort study. *Intern Emerg Med.* setembro de
617 2021;16(6):1573–82.
- 618 43. Pitre T, Van Alstine R, Chick G, Leung G, Mikhail D, Cusano E, et al. Antiviral drug
619 treatment for nonsevere COVID-19: a systematic review and network meta-analysis. *CMAJ.*
620 25 de julho de 2022;194(28):E969–80.

- 621 44. Wong CKH, Lau KTK, Leung GM. Real-world effectiveness of nirmatrelvir–ritonavir against
622 BA.4 and BA.5 omicron SARS-CoV-2 variants. *Lancet Infect Dis.* fevereiro de 2023;
- 623 45. Pepperrell T, Ellis L, Wang J, Hill A. Barriers to Worldwide Access for Paxlovid, a New
624 Treatment for COVID-19. *Open Forum Infect Dis.* 2 de setembro de 2022;9(9).
- 625 46. Conti V, Sellitto C, Torsiello M, Manzo V, De Bellis E, Stefanelli B, et al. Identification of
626 Drug Interaction Adverse Events in Patients With COVID-19. *JAMA Netw Open.* 19 de abril
627 de 2022;5(4):e227970.
- 628 47. Wong GL-H, Yip TC-F, Lai MS-M, Wong VW-S, Hui DS-C, Lui GC-Y. Incidence of Viral
629 Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir. *JAMA Netw Open.*
630 6 de dezembro de 2022;5(12):e2245086.
- 631 48. Wang L, Volkow ND, Davis PB, Berger NA, Kaelber DC, Xu R. COVID-19 rebound after
632 Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period.
633 *medRxiv Prepr Serv Heal Sci.* 6 de agosto de 2022;
- 634 49. Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. COVID-19 rebound after
635 Paxlovid and Molnupiravir during January-June 2022. *medRxiv Prepr Serv Heal Sci.* 22 de
636 junho de 2022;
- 637 50. Ranganath N, O’Horo JC, Challener DW, Tulledge-Scheitel SM, Pike ML, O’Brien M, et al.
638 Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019
639 (COVID-19) in High-Risk Persons. *Clin Infect Dis.* 14 de junho de 2022;
- 640 51. Medicines Patent Pool (MPP). 35 generic manufacturers sign agreements with MPP to
641 produce low-cost, generic versions of Pfizer’s oral COVID-19 treatment nirmatrelvir in
642 combination with ritonavir for supply in 95 low- and middle-income countries [Internet].
643 Available at: <https://medicinespatentpool.org/news-publications-post/35-generic->


644 manufacturers-sign-agreements-with-mpp-to-produce-low-cost-generic-versions-of-pfizers-
645 oral-covid-19-treatment-nirmatrelvir-in-combination-with-ritonavir-for-supply-in-95-low-and
646 52. Reuters. Generic drugmakers to sell Pfizer’s Paxlovid for \$25 or less in low-income countries
647 [Internet]. Available at: [https://www.reuters.com/business/healthcare-
648 pharmaceuticals/generic-drugmakers-sell-pfizers-paxlovid-25-or-less-low-income-countries-
649 2022-05-12/](https://www.reuters.com/business/healthcare-pharmaceuticals/generic-drugmakers-sell-pfizers-paxlovid-25-or-less-low-income-countries-2022-05-12/)

650 **Supporting information**


651 **S1 File – Contains PRISMA checklist, supporting materials, tables and figures**




A




B





A




B








A



B



Identification of studies via databases and registers

Identification of studies via other methods

Identification

Records identified from*:
PubMed (n = 43)
Embase (n = 126)
Cochrane (n = 13)

Records removed *before screening*:
Duplicate records removed
(n = 21)

Records identified from:
Citation searching (n = 1)

Screening

Records screened
(n = 161)

Records excluded**
(n = 130)

Reports sought for retrieval
(n = 31)

Reports not retrieved
(n = 0)

Reports sought for retrieval
(n = 1)

Reports not retrieved
(n = 0)

Reports assessed for eligibility
(n = 31)

Reports excluded:
Type of study (n = 16)

Reports assessed for eligibility
(n = 1)

Reports excluded:
(n = 0)

Included

Studies included in review
(n = 16)
Reports of included studies
(n = 16)

